Radiation Impact on Thromboembolic Events

Institut de Cancérologie de la Loire450 enrolled

Overview

The aim of the present study is to determine the frequency and to identify main risk factors for venous thromboembolism of venous thromboembolic complications in a population of cancer patients treated with a curative intent by ionizing radiation.

Study Type

OBSERVATIONAL

Enrollment

450

Conditions

Malignant Neoplasm

Interventions

Biomarkers assaysBIOLOGICAL

D-Dimer assays, C-reactive protein, blood platelets assays

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patient with a solid cancer (all locations) treated with radiation therapy and / or brachytherapy as curative intent * to be 18 Exclusion Criteria: * Patient with metastatic cancer, * Patients whose follow-up at 6 months is not possible * Patient receiving an anti-coagulative medication (curative doses) * Pregnant or breastfeeding women, * Person under protection of justice or unable to give consent

Locations (2)

CH de Roanne

Roanne, France

Institut de cancérologie Lucien Neuwirth

Saint-Priest-en-Jarez, France

Outcomes

Primary Outcomes

Venous Thromboembolism event

All venous thromboembolism, whether symptomatic or discovered incidentally, objectified (CT angiography, lung scintigraphy, venous Doppler) between J1 of radiation treatment, up to 6 months following discontinuation of radiation treatment

Time frame: 6 months

Secondary Outcomes

Dosage of D-dimer

Time frame: 6 months

C-reactive protein

Time frame: 6 months

Complete blood count

Time frame: 6 months

Time of occurrence of VTE

Time frame: 6 months

Symptomatic VTE

Symptomatic VTE.

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.